KV Pharmaceutical, Purdue Pharma settle painkiller patent dispute - Business Courier of Cincinnati:

loxezop.wordpress.com
Under the settlement, KV agreed to no longer disputsethe “validity, enforceability or infringement” of the Purdue genericf oxycodone patents. In return, Purduw granted KV a limited, non-exclusivre license to manufacture and in theUnited States, a certain amount of variouse dosage strengths of the drugs as long as KV pays royalties to KV also reached a deal to be an authorized, non-exclusive distributor in the United States of certain generic versions of OxyContin. Thesew agreements settle three patent infringementlawsuits Conn.-based Purdue filed against KV in 2007. KV still faces more lawsuits from other consumersand shareholders. Three individuals in St.
Clair County Circuit Court against KV, allegingy that certain drugs contained a potentially lethal amount of morphines due to oversized tablets that were eventuallyh recalled by thepharmaceutical company. Last month, , a Florida-basedx dermatology company, sued KV, of a patenr for Duac topical gel, an acne medication. KV also faces lawsuitsz from shareholders about manufacturing compliance andthe company’ws financial prospects. Brentwood, Mo.-based KV has and recalled painkillers.
In KV said it with the FDA that outlines a series of measure that will permit KV and its subsidiariea to resume manufacturingand